Esophageal Cancer
High-dose radiation combined with Nedaplatin and 5-FU is a safe and effective
Published in Clinical Oncology Week, August 18th, 2003
"From January 1999 to November 2000, a total of 24 esophageal cancer patients (17 untreated and seven recurrent cases) were treated with radiation therapy (60-70 Gy) combined with cis-diammine-glycolatoplatinum (Nedaplatin) (80-120 mg/body) and 5-fluorouracil (5-FU) (500-1,000 mg/body/24 h, continuous infusion for 5 days)," researchers in Japan report.
"Grade III leukocytopenia was observed in six (25%) of the patients. Grade III and IV thrombocytopenia was observed in one patient each," wrote K. Nemoto and colleagues, Tohoku University, School of Medicine.
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
More Articles from Clinical Oncology Week
- Adult Cancer
Psychosocial interventions improve quality of life in adult cancer patients - Leukemia
NSAID use may be associated with risk of adult leukemia - Colorectal Cancer
Study affirms safety of oxaliplatin for advanced disease - Endometrial Cancer
Study examines relation of possible prognostic indicators with clinical signs - Multiple Neoplasms
Older cancer patients may be at higher risk of developing second primaries - Pilocytic Astrocytoma
Protein can predict progression of most common childhood brain tumor - More from this issue of Clinical Oncology Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
